Johnson & Johnson’s COVID-19 vaccine: Answering the big questions

As we begin the month of March, it’s hard to believe COVID-19 has impacted our lives for a full year. In December 2020, we saw a light at the end of the tunnel as two vaccines – produced by Pfizer and BioNTech and Moderna – were approved by the Food and Drug Administration (FDA) for emergency use in the United States and distribution began. Now, we have another vaccine in our arsenal. On Feb. 27, the FDA granted emergency use authorization for Johnson & Johnson’s coronavirus vaccine. The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) also endorsed its use in the U.S. This is the first vaccine currently available that comes in a single dose. As a vaccine developer and researcher, I’m incredibly encouraged by the progress made thus far as we continue in our fight against COVID-19. Following the recent news regarding this third vaccine, I wanted to share some of the most common questions about Johnson & Johnson’s vaccine.